Prestige Biopharma Group

07/02/2023

The final analysis of the phase 3 clinical trial of Prestige Biopharma's Herceptin biosimilar 'HD201 (Tuznue)' is published on BMC Cancer: https://bmccancer.biomedcentral.com/articles/10.1186/s12885-023-10574-2

This final analysis further confirms the comparable efficacy and safety of HD201 and trastuzumab.

Currently, we're focusing on getting the marketing authorisation for HD201 in various regions including US, Europe, Canada, and Korea. Keep fingers crossed that we could help more patients around the world by adding an affordable treatment option.

Background The TROIKA trial established that HD201 and trastuzumab were equivalent in terms of primary endpoints (total pathological complete response) following neoadjuvant treatment. The objective of the present analysis was to compare survival outcomes and final safety. Methods In the TROIKA tria...

16/01/2023

Prestige Biologics at from 16th to 20th January in San Diego!
Visit our booth #802 and discuss your challenges. We're here to find the best solution as a reliable

10/01/2023

Under our motto "Innovation for Life", Prestige Biopharma is dedicated to bringing new drugs to treat the deadliest diseases.

Here comes another milestone of our journey: we are proud to announce that Prestige Biopharma obtained a patent in Korea for our novel antibody PBP1710 (anti-CTHRC1) for solid cancer treatment.

Solid tumors including pancreatic cancer, express abnormally high levels of CTHRC1 (collagen triple helix repeat containing 1), a protein that facilitates cancer cell migration and growth. PBP1710 specifically binds to CTHRC1 and exerts anti-metastasis and anti-tumor growth effects.

According to IDC (Innovative Discover Centre) at Prestige Biopharma, PBP1710 has shown remarkable research results on a cellular level, reducing cancer cell migration and invasion by approximately 45% in solid cancer such as pancreatic cancer, ovarian cancer, breast cancer and colorectal cancer. As a next-generation antibody drug, PBP1710 expected to greatly contribute to improving treatment of cancer and survival of patients, particularly in combination with other cancer treatments.

PBP1710 is currently under review for patent registration in 21 other countries and regions including the US, Europe, Japan, and China.

10/01/2023

Prestige Biologics starting off the journey in US by joining the ‘BIO Partnering at Bio Partnering’ in San Francisco from Jan 9 to 12!

‘BIO Partnering at JP Morgan’ is linked to the JP Morgan Healthcare Conference, the world’s largest bio investment event, attended by a wide range of biopharmaceutical companies and investors around the globe to build network and discuss partnership.

Looking forward to discovering many new potential clients and finding partnership opportunities, Prestige Biologics is having one-on-one meetings with numbers of potential clients to attract partnership discussions, particularly aiming at drug developers looking for customized, flexible and efficient biomanufacturing process.

Connect with us and learn more about this innovative CDMO with proprietary 'ALITA Smart BioFactory' technology and innovative CDEMO service!

17/11/2022

Have a closer look of Prestige Biopharma Innovative Discovery Centre (IDC) in Busan, Korea: https://lnkd.in/gWQffTNA by Free Economic Zones
Our colleagues will tell you everything: who we are, what we do, where we aim, and how we are going to make it!

BJFEZ tenant company Prestige Biopharma tells everything about Myeongji International City✍00:31 Introduction to the company, ‘Prestige Biopharma (PBP)’01:30...

31/10/2022

Check out our latest corporate video and learn more about Prestige Biopharma Group: https://youtu.be/uQgbpyh2xxg

Our full value chain covers from drug discovery and development to manufacturing and production. Meet Prestige Biopharma's promising pipeline and Prestige Biologics' solutions.

Connect with us at !

Connect with us at CPhI Frankfurt 2022

25/10/2022

Prestige Biologics at BIO-EUROPE in Leipzig, Germany from 24 to 26 October - Connect with us at Booth #104!

20/10/2022

Prestige Biologics is leading in the industry.
At the "Global GMP Establishment Success Seminar" today, Keumbae Jung, Team Leader in Digital Transformation, gave a presentation on 'How to successfully establish a digital bio platform' in business, sharing some insight and experience on introducing digital solutions throughout the end-to-end process from design, construction, adaption to stabilization.
We're getting faster, smarter, stronger with !

18/10/2022

Prestige Biologics is joining from October 24 to 26 in Leipziger, Germany. Visit booth #104 and find one-stop solution for you and your drug!